- Exploratory Phase 1b/2 trial targeting a heterogeneous population of patients with HPV16-positive, recurrent and/or metastatic cancer whose disease has progressed after up to three lines of chemotherapy, reports promising clinical activity with the combination regimen.
- Patient follow-up and translational analyses are ongoing.
- Full results will be presented at an upcoming scientific conference.
- Transgene intends to continue the clinical development of TG4001 in a larger, controlled confirmatory study.
Conference call scheduled on July 22 at 6:15 p.m. CET (details at the end of the release)
Strasbourg, France, July 22, 2020, 4:30 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, performed a pooled analysis of the data from the Phase 1b/2 trial combining TG4001, a HPV16 targeted therapeutic vaccine, with avelumab (BAVENCIO®), a human anti-PD-L1 antibody, in HPV16-positive recurrent and/or metastatic malignancies. This analysis confirms that TG4001 can be safely combined with an immune checkpoint inhibitor and shows clinical activity of this combination regimen. The trial is being conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer.
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer